Efficacy of Reboxetin in childhood and adolescence with ADHD and Anxiety disorder in out-patient clinic

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138905033979N3

Enrollment

Registered

2011-01-31

Start date

2009-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit disorder with hyperactivity and anxity.

Interventions

Reboxitine 4 mg tablet twice daily.

Treatment - Drugs

Reboxitine 4 mg tablet twice daily

Eligibility

Sex/Gender

All

Age

6 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: ADHD and Anxeity disorder except for OCD and PTSD Exclusion criteria: MR, presence of any medical problems, other psychotic disorder, drug or substance use

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Attention deficit hyperactivity disorder. Timepoint: at the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: The Conner's parent rating scale–revised short version [CPRS –R(S)] scores.;Anxiety. Timepoint: At the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: The Hamilton anxiety rating scale scores.	—

Measure

Time frame

Attention deficit hyperactivity disorder. Timepoint: at the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: The Conner's parent rating scale–revised short version [CPRS –R(S)] scores.;Anxiety. Timepoint: At the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: The Hamilton anxiety rating scale scores.

—

Secondary

Measure	Time frame
Rate of diastolic and systolic blood pressure. Timepoint: at the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: Assessment of peripheral blood pressure with blood pressure monitor.;Rate of side effects. Timepoint: at the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: based on Pharmaceutical list.;Pulse rate. Timepoint: at the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: Assessment of Peripheral pulse rate.	—

Measure

Time frame

Rate of diastolic and systolic blood pressure. Timepoint: at the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: Assessment of peripheral blood pressure with blood pressure monitor.;Rate of side effects. Timepoint: at the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: based on Pharmaceutical list.;Pulse rate. Timepoint: at the beginning (baseline) and the end of second and fourth weeks of the study. Method of measurement: Assessment of Peripheral pulse rate.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForugh Riahi

Ahvaz Jondishapoor Medical University

riahi13@gmail.com ,riahi-f@ajums.ac.ir+98 61 1374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026